Amylyx Pharmaceuticals (AMLX) EBITDA (2021 - 2026)

Amylyx Pharmaceuticals' EBITDA history runs 6 years deep, the most recent figure standing at -$41.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 15.73% year-over-year to -$41.4 million; the TTM figure through Mar 2026 stood at -$34.0 million (down 248.82% YoY), while the FY2025 annual figure was -$30.4 million, up 52.11% from the prior year.
• EBITDA was -$41.4 million for Q1 2026 at Amylyx Pharmaceuticals, down from $86.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $210.6 million in Q4 2024 to a low of -$122.1 million in Q1 2024.
• Historically, EBITDA has averaged -$17.4 million across 5 years, with a median of -$41.4 million in 2026.
• Biggest YoY gain for EBITDA was 10790.8% in 2024; the steepest drop was 5848.86% in 2024.
• A 5-year view of EBITDA shows it stood at -$44.6 million in 2022, then surged by 104.34% to $1.9 million in 2023, then jumped by 10790.8% to $210.6 million in 2024, then slumped by 59.03% to $86.3 million in 2025, then slumped by 148.03% to -$41.4 million in 2026.
• The last three EBITDA figures came in at -$41.4 million (Q1 2026), $86.3 million (Q4 2025), and -$36.0 million (Q3 2025), per Business Quant data.